<?xml version="1.0" encoding="UTF-8" standalone="no"?><document id="DDI-DrugBank.d478">
    <sentence id="DDI-DrugBank.d478.s0" text="Ergot-containing drugs have been reported to cause prolonged vasospastic reactions.">
        <entity charOffset="0-4" id="DDI-DrugBank.d478.s0.e0" text="Ergot" type="group"/>
    </sentence>
    <sentence id="DDI-DrugBank.d478.s1" text="Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.">
        <entity charOffset="80-89" id="DDI-DrugBank.d478.s1.e0" text="ergotamine" type="drug"/>
        <entity charOffset="105-126" id="DDI-DrugBank.d478.s1.e1" text="ergot-type medications" type="group"/>
        <entity charOffset="134-150" id="DDI-DrugBank.d478.s1.e2" text="dihydroergotamine" type="drug"/>
        <entity charOffset="155-166" id="DDI-DrugBank.d478.s1.e3" text="methysergide" type="drug"/>
        <entity charOffset="173-183" id="DDI-DrugBank.d478.s1.e4" text="naratriptan" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d478.s1.e0" e2="DDI-DrugBank.d478.s1.e1" id="DDI-DrugBank.d478.s1.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d478.s1.e0" e2="DDI-DrugBank.d478.s1.e2" id="DDI-DrugBank.d478.s1.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d478.s1.e0" e2="DDI-DrugBank.d478.s1.e3" id="DDI-DrugBank.d478.s1.p2"/>
        <pair ddi="true" e1="DDI-DrugBank.d478.s1.e0" e2="DDI-DrugBank.d478.s1.e4" id="DDI-DrugBank.d478.s1.p3" type="advise"/>
        <pair ddi="false" e1="DDI-DrugBank.d478.s1.e1" e2="DDI-DrugBank.d478.s1.e2" id="DDI-DrugBank.d478.s1.p4"/>
        <pair ddi="false" e1="DDI-DrugBank.d478.s1.e1" e2="DDI-DrugBank.d478.s1.e3" id="DDI-DrugBank.d478.s1.p5"/>
        <pair ddi="true" e1="DDI-DrugBank.d478.s1.e1" e2="DDI-DrugBank.d478.s1.e4" id="DDI-DrugBank.d478.s1.p6" type="advise"/>
        <pair ddi="false" e1="DDI-DrugBank.d478.s1.e2" e2="DDI-DrugBank.d478.s1.e3" id="DDI-DrugBank.d478.s1.p7"/>
        <pair ddi="true" e1="DDI-DrugBank.d478.s1.e2" e2="DDI-DrugBank.d478.s1.e4" id="DDI-DrugBank.d478.s1.p8" type="advise"/>
        <pair ddi="true" e1="DDI-DrugBank.d478.s1.e3" e2="DDI-DrugBank.d478.s1.e4" id="DDI-DrugBank.d478.s1.p9" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d478.s2" text="The administration of naratriptan with other 5-HT1 agonists has not been evaluated in migraine patients.">
        <entity charOffset="22-32" id="DDI-DrugBank.d478.s2.e0" text="naratriptan" type="drug"/>
        <entity charOffset="45-58" id="DDI-DrugBank.d478.s2.e1" text="5-HT1 agonists" type="group"/>
        <pair ddi="false" e1="DDI-DrugBank.d478.s2.e0" e2="DDI-DrugBank.d478.s2.e1" id="DDI-DrugBank.d478.s2.p0"/>
    <negationtags>The administration of naratriptan with other 5-HT1 agonists has &lt;scope&gt; &lt;cue&gt; not &lt;/cue&gt; been evaluated in migraine patients. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d478.s3" text="Because their vasospastic effects may be additive, coadministration of naratriptan and other 5-HT1 agonists within 24 hours of each other is not recommended.">
        <entity charOffset="71-81" id="DDI-DrugBank.d478.s3.e0" text="naratriptan" type="drug"/>
        <entity charOffset="93-106" id="DDI-DrugBank.d478.s3.e1" text="5-HT1 agonists" type="group"/>
        <pair ddi="true" e1="DDI-DrugBank.d478.s3.e0" e2="DDI-DrugBank.d478.s3.e1" id="DDI-DrugBank.d478.s3.p0" type="advise"/>
    <negationtags>Because their vasospastic effects may be additive, coadministration of naratriptan and other 5-HT1 agonists within 24 hours of each other is &lt;scope&gt; &lt;cue&gt; not &lt;/cue&gt; recommended. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d478.s4" text="Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HTv agonists.">
        <entity charOffset="0-38" id="DDI-DrugBank.d478.s4.e0" text="Selective serotonin reuptake inhibitors" type="group"/>
        <entity charOffset="41-45" id="DDI-DrugBank.d478.s4.e1" text="SSRIs" type="group"/>
        <entity charOffset="55-64" id="DDI-DrugBank.d478.s4.e2" text="fluoxetine" type="drug"/>
        <entity charOffset="67-77" id="DDI-DrugBank.d478.s4.e3" text="fluvoxamine" type="drug"/>
        <entity charOffset="80-89" id="DDI-DrugBank.d478.s4.e4" text="paroxetine" type="drug"/>
        <entity charOffset="92-101" id="DDI-DrugBank.d478.s4.e5" text="sertraline" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d478.s4.e0" e2="DDI-DrugBank.d478.s4.e1" id="DDI-DrugBank.d478.s4.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d478.s4.e0" e2="DDI-DrugBank.d478.s4.e2" id="DDI-DrugBank.d478.s4.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d478.s4.e0" e2="DDI-DrugBank.d478.s4.e3" id="DDI-DrugBank.d478.s4.p2"/>
        <pair ddi="false" e1="DDI-DrugBank.d478.s4.e0" e2="DDI-DrugBank.d478.s4.e4" id="DDI-DrugBank.d478.s4.p3"/>
        <pair ddi="false" e1="DDI-DrugBank.d478.s4.e0" e2="DDI-DrugBank.d478.s4.e5" id="DDI-DrugBank.d478.s4.p4"/>
        <pair ddi="false" e1="DDI-DrugBank.d478.s4.e1" e2="DDI-DrugBank.d478.s4.e2" id="DDI-DrugBank.d478.s4.p5"/>
        <pair ddi="false" e1="DDI-DrugBank.d478.s4.e1" e2="DDI-DrugBank.d478.s4.e3" id="DDI-DrugBank.d478.s4.p6"/>
        <pair ddi="false" e1="DDI-DrugBank.d478.s4.e1" e2="DDI-DrugBank.d478.s4.e4" id="DDI-DrugBank.d478.s4.p7"/>
        <pair ddi="false" e1="DDI-DrugBank.d478.s4.e1" e2="DDI-DrugBank.d478.s4.e5" id="DDI-DrugBank.d478.s4.p8"/>
        <pair ddi="false" e1="DDI-DrugBank.d478.s4.e2" e2="DDI-DrugBank.d478.s4.e3" id="DDI-DrugBank.d478.s4.p9"/>
        <pair ddi="false" e1="DDI-DrugBank.d478.s4.e2" e2="DDI-DrugBank.d478.s4.e4" id="DDI-DrugBank.d478.s4.p10"/>
        <pair ddi="false" e1="DDI-DrugBank.d478.s4.e2" e2="DDI-DrugBank.d478.s4.e5" id="DDI-DrugBank.d478.s4.p11"/>
        <pair ddi="false" e1="DDI-DrugBank.d478.s4.e3" e2="DDI-DrugBank.d478.s4.e4" id="DDI-DrugBank.d478.s4.p12"/>
        <pair ddi="false" e1="DDI-DrugBank.d478.s4.e3" e2="DDI-DrugBank.d478.s4.e5" id="DDI-DrugBank.d478.s4.p13"/>
        <pair ddi="false" e1="DDI-DrugBank.d478.s4.e4" e2="DDI-DrugBank.d478.s4.e5" id="DDI-DrugBank.d478.s4.p14"/>
    </sentence>
    <sentence id="DDI-DrugBank.d478.s5" text="If concomitant treatment with naratriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.">
        <entity charOffset="30-40" id="DDI-DrugBank.d478.s5.e0" text="naratriptan" type="drug"/>
        <entity charOffset="49-52" id="DDI-DrugBank.d478.s5.e1" text="SSRI" type="group"/>
        <pair ddi="true" e1="DDI-DrugBank.d478.s5.e0" e2="DDI-DrugBank.d478.s5.e1" id="DDI-DrugBank.d478.s5.p0" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d478.s6" text="Drug/ Laboratory Test Interactions AMERGE Tablets are not known to interfere with commonly employed clinical laboratory tests.">
        <entity charOffset="35-40" id="DDI-DrugBank.d478.s6.e0" text="AMERGE" type="brand"/>
    <negationtags>Drug/ Laboratory Test Interactions AMERGE Tablets are &lt;scope&gt; &lt;cue&gt; not &lt;/cue&gt; known to interfere with commonly employed clinical laboratory tests. &lt;/scope&gt;</negationtags></sentence>
</document>